Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 17 | 2010 | 4781 | 0.260 |
Why?
|
| Carcinoma | 10 | 2002 | 2343 | 0.250 |
Why?
|
| Fallopian Tube Neoplasms | 2 | 1998 | 324 | 0.150 |
Why?
|
| Endometrial Neoplasms | 6 | 1999 | 1338 | 0.090 |
Why?
|
| Adenocarcinoma | 10 | 2010 | 6257 | 0.090 |
Why?
|
| Cell Fusion | 3 | 2005 | 293 | 0.090 |
Why?
|
| Dendritic Cells | 3 | 2005 | 2676 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2010 | 11436 | 0.070 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 1996 | 220 | 0.060 |
Why?
|
| Registries | 2 | 1999 | 7932 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2000 | 9141 | 0.060 |
Why?
|
| Uterine Neoplasms | 5 | 1993 | 1492 | 0.050 |
Why?
|
| Neoplasm Staging | 13 | 1999 | 10946 | 0.050 |
Why?
|
| Cisplatin | 5 | 2010 | 1632 | 0.050 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2002 | 345 | 0.050 |
Why?
|
| Prognosis | 15 | 2010 | 28548 | 0.050 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2000 | 513 | 0.050 |
Why?
|
| Frozen Sections | 1 | 2000 | 153 | 0.040 |
Why?
|
| Combined Modality Therapy | 10 | 2000 | 8475 | 0.040 |
Why?
|
| Serpins | 1 | 1981 | 236 | 0.040 |
Why?
|
| Lymphocyte Activation | 3 | 2005 | 5383 | 0.040 |
Why?
|
| Antigens | 1 | 2004 | 1440 | 0.040 |
Why?
|
| Pelvic Inflammatory Disease | 2 | 1998 | 94 | 0.040 |
Why?
|
| Condylomata Acuminata | 2 | 1991 | 76 | 0.040 |
Why?
|
| Uterus | 2 | 1989 | 672 | 0.040 |
Why?
|
| Isoantigens | 1 | 2000 | 496 | 0.040 |
Why?
|
| Endometrium | 1 | 1981 | 415 | 0.040 |
Why?
|
| Epithelium | 2 | 1999 | 1639 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 1022 | 0.040 |
Why?
|
| Survival Analysis | 7 | 2000 | 10060 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 2002 | 1609 | 0.040 |
Why?
|
| Integrins | 1 | 2002 | 842 | 0.040 |
Why?
|
| Glycoproteins | 2 | 1984 | 2211 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2002 | 1498 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2000 | 1336 | 0.030 |
Why?
|
| Progesterone | 1 | 1981 | 762 | 0.030 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 1995 | 56 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 2000 | 519 | 0.030 |
Why?
|
| Ovarian Diseases | 1 | 1996 | 138 | 0.030 |
Why?
|
| Fertility | 1 | 1999 | 764 | 0.030 |
Why?
|
| Neoplasm Seeding | 1 | 1994 | 85 | 0.030 |
Why?
|
| Pregnancy, Abdominal | 1 | 1973 | 6 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2002 | 1974 | 0.030 |
Why?
|
| Cystadenoma, Mucinous | 1 | 1993 | 61 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2000 | 1260 | 0.030 |
Why?
|
| Postoperative Care | 2 | 1996 | 1464 | 0.030 |
Why?
|
| Carcinoma, Endometrioid | 1 | 1996 | 271 | 0.030 |
Why?
|
| Cystadenoma, Serous | 1 | 1993 | 101 | 0.030 |
Why?
|
| Age of Onset | 1 | 1999 | 3219 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2005 | 1769 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 1998 | 3444 | 0.030 |
Why?
|
| Female | 36 | 2010 | 376708 | 0.030 |
Why?
|
| Vaginal Neoplasms | 1 | 1991 | 105 | 0.020 |
Why?
|
| Leiomyosarcoma | 2 | 1993 | 476 | 0.020 |
Why?
|
| Vaginal Diseases | 1 | 1991 | 103 | 0.020 |
Why?
|
| Fluorouracil | 2 | 1994 | 1576 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 4444 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 1997 | 2906 | 0.020 |
Why?
|
| Adult | 22 | 2010 | 212371 | 0.020 |
Why?
|
| Lymph Nodes | 3 | 1997 | 3443 | 0.020 |
Why?
|
| Anura | 1 | 1969 | 81 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2005 | 861 | 0.020 |
Why?
|
| Retrospective Studies | 13 | 2000 | 76887 | 0.020 |
Why?
|
| Hysterectomy | 3 | 1997 | 915 | 0.020 |
Why?
|
| Paclitaxel | 2 | 2010 | 1678 | 0.020 |
Why?
|
| Cyclophosphamide | 2 | 2010 | 2191 | 0.020 |
Why?
|
| Abortion, Induced | 1 | 1973 | 444 | 0.020 |
Why?
|
| Sarcoma | 2 | 1993 | 1868 | 0.020 |
Why?
|
| Endometriosis | 1 | 1996 | 840 | 0.020 |
Why?
|
| Aged | 20 | 2010 | 161495 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 1994 | 1170 | 0.020 |
Why?
|
| Middle Aged | 23 | 2010 | 211305 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 9952 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1993 | 593 | 0.020 |
Why?
|
| Humans | 36 | 2010 | 735458 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2004 | 20517 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1996 | 2814 | 0.020 |
Why?
|
| Proteins | 1 | 1981 | 5975 | 0.020 |
Why?
|
| Optic Nerve | 1 | 1969 | 555 | 0.020 |
Why?
|
| Radioimmunoassay | 2 | 2002 | 875 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1997 | 1997 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 1998 | 12840 | 0.020 |
Why?
|
| Aged, 80 and over | 10 | 2000 | 56770 | 0.010 |
Why?
|
| Ureteral Neoplasms | 1 | 1985 | 110 | 0.010 |
Why?
|
| Cell Shape | 1 | 2004 | 374 | 0.010 |
Why?
|
| Carcinoma, Papillary | 1 | 1989 | 775 | 0.010 |
Why?
|
| Survival Rate | 4 | 1999 | 12513 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2004 | 696 | 0.010 |
Why?
|
| Adenoma | 1 | 1993 | 2122 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2004 | 949 | 0.010 |
Why?
|
| Integrin alpha6beta4 | 1 | 2002 | 31 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2000 | 5376 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 4846 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 1997 | 1750 | 0.010 |
Why?
|
| Brachytherapy | 2 | 2000 | 1229 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 2002 | 280 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2004 | 1416 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2000 | 323 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1996 | 3976 | 0.010 |
Why?
|
| Doxorubicin | 2 | 1999 | 2196 | 0.010 |
Why?
|
| Adnexa Uteri | 1 | 1979 | 44 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1981 | 2212 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1981 | 1763 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2004 | 1336 | 0.010 |
Why?
|
| Parity | 1 | 1981 | 910 | 0.010 |
Why?
|
| Radiotherapy | 2 | 2000 | 1503 | 0.010 |
Why?
|
| Adnexal Diseases | 1 | 1979 | 101 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 2000 | 747 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2000 | 1315 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1999 | 618 | 0.010 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2000 | 454 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2000 | 1840 | 0.010 |
Why?
|
| Rabbits | 1 | 2002 | 4826 | 0.010 |
Why?
|
| Treatment Outcome | 4 | 2010 | 62430 | 0.010 |
Why?
|
| Peritoneal Lavage | 1 | 1994 | 33 | 0.010 |
Why?
|
| Operating Rooms | 1 | 2000 | 783 | 0.010 |
Why?
|
| Ascitic Fluid | 1 | 1994 | 195 | 0.010 |
Why?
|
| Amniocentesis | 1 | 1973 | 116 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 1994 | 341 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1984 | 3672 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2005 | 4264 | 0.010 |
Why?
|
| Hormones | 1 | 1996 | 874 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 6142 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 1984 | 3627 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1985 | 2234 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 4433 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1973 | 611 | 0.010 |
Why?
|
| Neurons | 1 | 1969 | 9240 | 0.010 |
Why?
|
| Premenopause | 1 | 1993 | 1023 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1969 | 110 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 18842 | 0.010 |
Why?
|
| Follow-Up Studies | 3 | 1995 | 38356 | 0.010 |
Why?
|
| Histological Techniques | 1 | 1969 | 197 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1991 | 1636 | 0.010 |
Why?
|
| Urinary Bladder | 2 | 1985 | 1164 | 0.000 |
Why?
|
| Radiotherapy Dosage | 2 | 1986 | 2854 | 0.000 |
Why?
|
| Membrane Proteins | 1 | 2004 | 7748 | 0.000 |
Why?
|
| Adolescent | 4 | 2000 | 85125 | 0.000 |
Why?
|
| Mathematics | 1 | 1969 | 709 | 0.000 |
Why?
|
| Radiation Dosage | 1 | 1996 | 1909 | 0.000 |
Why?
|
| Recurrence | 1 | 1999 | 8232 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 14501 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1979 | 5879 | 0.000 |
Why?
|
| Vaginal Smears | 1 | 1989 | 503 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1995 | 6306 | 0.000 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1993 | 973 | 0.000 |
Why?
|
| Neoplasms, Second Primary | 1 | 1993 | 1048 | 0.000 |
Why?
|
| Logistic Models | 1 | 2000 | 13074 | 0.000 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1985 | 116 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1969 | 2603 | 0.000 |
Why?
|
| Disease-Free Survival | 1 | 1996 | 6779 | 0.000 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2000 | 5135 | 0.000 |
Why?
|
| Vulva | 1 | 1985 | 82 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 9086 | 0.000 |
Why?
|
| Myelin Sheath | 1 | 1969 | 640 | 0.000 |
Why?
|
| Cystoscopy | 1 | 1985 | 133 | 0.000 |
Why?
|
| Methods | 1 | 1985 | 1109 | 0.000 |
Why?
|
| Glycoside Hydrolases | 1 | 1984 | 133 | 0.000 |
Why?
|
| Postmenopause | 1 | 1993 | 2445 | 0.000 |
Why?
|
| Neuraminidase | 1 | 1984 | 204 | 0.000 |
Why?
|
| Neoplasm Metastasis | 2 | 1985 | 4805 | 0.000 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1985 | 294 | 0.000 |
Why?
|
| Reoperation | 1 | 1993 | 4209 | 0.000 |
Why?
|
| Diaphragm | 1 | 1985 | 350 | 0.000 |
Why?
|
| Disease Progression | 1 | 2000 | 13117 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 1999 | 14815 | 0.000 |
Why?
|
| Body Fluids | 1 | 1984 | 316 | 0.000 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 1969 | 950 | 0.000 |
Why?
|
| Ureter | 1 | 1985 | 369 | 0.000 |
Why?
|
| Laparoscopy | 2 | 1985 | 2113 | 0.000 |
Why?
|
| Vagina | 1 | 1985 | 806 | 0.000 |
Why?
|
| Proportional Hazards Models | 1 | 1994 | 12113 | 0.000 |
Why?
|
| Neoplasms, Experimental | 1 | 1984 | 1226 | 0.000 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1984 | 496 | 0.000 |
Why?
|
| Time Factors | 2 | 1994 | 39212 | 0.000 |
Why?
|
| Radiation Injuries | 1 | 1986 | 1167 | 0.000 |
Why?
|
| Epitopes | 1 | 1984 | 2496 | 0.000 |
Why?
|
| Neoplasm Invasiveness | 1 | 1986 | 3580 | 0.000 |
Why?
|
| Incidence | 1 | 1996 | 20493 | 0.000 |
Why?
|
| Cohort Studies | 1 | 1999 | 39931 | 0.000 |
Why?
|
| Antibodies | 1 | 1984 | 2402 | 0.000 |
Why?
|
| Neoplasms | 1 | 1984 | 21375 | 0.000 |
Why?
|
| Intestines | 1 | 1985 | 1881 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1984 | 2233 | 0.000 |
Why?
|
| Mice | 1 | 2002 | 79548 | 0.000 |
Why?
|
| Animals | 2 | 2002 | 165479 | 0.000 |
Why?
|
| Ovary | 1 | 1979 | 959 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1996 | 13478 | 0.000 |
Why?
|
| Pregnancy | 1 | 1973 | 28985 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1994 | 15156 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1984 | 8256 | 0.000 |
Why?
|
| Palliative Care | 1 | 1985 | 3465 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1985 | 4463 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1985 | 7764 | 0.000 |
Why?
|
| Age Factors | 1 | 1985 | 17982 | 0.000 |
Why?
|
Concepts
(195)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(11)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_